Patient Input Is Requested by CADTH on Gilead’s Combo of Sofosbuvir and Velpatasvir for Genotypes 1, 3 and 4

We want to hear your voice! Patient input is requested by CADTH on Gilead’s combo of sofosbuvir and velpatasvir for genotypes 1, 3 and 4.  ANYONE AFFECTED BY HEPATITIS C CAN SUBMIT; it doesn't matter which genotype you are, or if you haven't had any experience with this new treatment. Gilead’s combo is pan-genotypic (works for all genotypes).  Check out the background information below to see the results from clinical trials to date. You will see that the

Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals

Sofosbuvir/velpatasvir, a forthcoming combination that effectively treats all hepatitis C virus (HCV) genotypes, can be safely used with most boosted antiretrovirals for people with HIV and HCV co-infection, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston.About one-third of people living with HIV also have HCV. New direct-acting antivirals (DAAs) used in interferon-free regimens

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir

-- Final FDA Decision Anticipated by June 28, 2016 --FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 4, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® in December 2013, and velpatasvir (VE...

Combination therapy successfully treats hepatitis C in patients with advanced liver disease

A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the study was co-led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Intermountain Medical Center and published online Nov. 17 in The New England Journal of Medicine (NEJM). "More than half of the patients in the study